Unlocking the Potential of FTH1P11: A Promising Drug Target and Biomarker
Unlocking the Potential of FTH1P11: A Promising Drug Target and Biomarker
Introduction
Ferritin, a protein produced by the liver, is widely recognized for its role in wound healing, inflammation, and bone growth. It is composed of four polypeptide chains, each with distinct functions. The heavy polypeptide 1 (FP1) pseudogene 11 is a unique gene that encodes the FP1 chain. In this article, we will explore the potential of FTH1P11 as a drug target and biomarker.
Understanding FTH1P11: The Structure and Function of the FP1 Chain
FP1 is a key component of ferritin, as it contributes to the formation of the protein. The FP1 chain has four distinct regions: an N-terminus, a catalytic center, a transmembrane region, and a C-terminus. The N-terminus is responsible for the protein's stability, while the catalytic center is the site of the protein's unique catalytic activity. The transmembrane region is responsible for the protein's solubility and stability, while the C-terminus is responsible for the protein's stability and for interactions with other proteins effect.
Expression and Regulation of FTH1P11
FP1 expression is typically highest in the liver and other tissues, such as the heart, pancreas, and skeletal muscles. The gene is also expressed in other organs, including the kidneys, lungs, and gastrointestinal tract. Factors that regulate FP1 expression include transcription factors , such as RNA polymerase (RNA polymerase, RNA-protein complex), promoter enhancer, etc.
The translation products of FP1 are FP1-alpha, FP1-beta, FP1-gamma and FP1-epsilon. These subunits form the complete ferritin molecule in different ways. The FP1-alpha chain forms a separate polypeptide chain through an 伪-helical structure and is connected by disulfide bonds with the FP1-beta chain and FP1-gamma chain. FP1-beta chain and FP1-gamma chain are intertwined in the 伪-helical structure and form a continuous 尾-sheet. The FP1-epsilon chain is a shorter 蔚-helical structure connected to the FP1-alpha chain.
The functions of FP1 include stimulating cell growth, promoting cell apoptosis, regulating immune cell activity and anti-tumor activity. These functions make FP1 an attractive drug target.
DPP4 (Deleted in a mouse model of colon cancer) binds to the FP1-alpha chain, inhibits the 伪-helical structure, and leads to ubiquitination of the FP1-alpha chain. Ubiquitination is a common protein modification method, which refers to multi-level modifications on proteins, including phosphorylation, protein binding, and glycosylation. The binding of DPP4 will lead to a decrease in the stability of the FP1-alpha chain and may affect the biological activity of FP1.
Interactions between FP1 and drugs
FP1 has broad application prospects in drug research. For example, FP1 can be used as a target for cancer treatment. Scientists have discovered that FP1 can inhibit the formation of 伪-helical structures by binding to DPP4, thereby inhibiting the growth of cancer cells. Some studies have also shown that FP1 can inhibit apoptosis and thus have a therapeutic effect on tumor cells with excessive cell proliferation.
In addition, FP1 can also be used as a tumor biomarker. Since FP1 is expressed in a variety of tumors, it can be used to detect the presence of tumors and monitor tumor development. In addition, FP1 can also be used as a monitoring indicator of drug efficacy.
Protein Name: Ferritin Heavy Chain 1 Pseudogene 11
The "FTH1P11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FTH1P11 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
FTH1P12 | FTH1P2 | FTH1P20 | FTH1P22 | FTH1P24 | FTH1P3 | FTH1P4 | FTH1P5 | FTH1P7 | FTH1P8 | FTHL17 | FTL | FTLP16 | FTLP2 | FTLP3 | FTLP7 | FTMT | FTO | FTO-IT1 | FTOP1 | FTSJ1 | FTSJ3 | FTX | FUBP1 | FUBP3 | FUCA1 | FUCA2 | Fucosyl GM1 | Fucosyltransferase | FUNDC1 | FUNDC2 | FUNDC2P2 | FUNDC2P3 | FUOM | FURIN | FUS | FUT1 | FUT10 | FUT11 | FUT2 | FUT3 | FUT4 | FUT5 | FUT6 | FUT7 | FUT8 | FUT8-AS1 | FUT9 | FUZ | FXN | FXR1 | FXR2 | FXYD1 | FXYD2 | FXYD3 | FXYD4 | FXYD5 | FXYD6 | FXYD6-FXYD2 | FXYD7 | FYB1 | FYB2 | FYCO1 | FYN | FYTTD1 | FZD1 | FZD10 | FZD10-AS1 | FZD2 | FZD3 | FZD4 | FZD4-DT | FZD5 | FZD6 | FZD7 | FZD8 | FZD9 | FZR1 | G protein-Coupled Inwardly-Rectifying Potassium Channel (GIRK) | G Protein-Coupled Receptor Kinases (GRKs) | G0S2 | G2E3 | G2E3-AS1 | G3BP1 | G3BP2 | G6PC1 | G6PC2 | G6PC3 | G6PD | GA-binding protein | GAA | GAB1 | GAB2 | GAB3 | GAB4 | GABA(A) receptor | GABARAP | GABARAPL1 | GABARAPL2 | GABARAPL3
